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data set to facilitate interpretation and comparison of results 
from clinical studies, and of systematic data evaluation and 
meta-analyses. Editors of journals publishing such reports 
are encouraged to require the reporting of the minimum 
data set described here either in the main body of the pub-
lication or as supplementary online material.  
 © 2014 S. Karger AG, Basel 
 Introduction 
 The recently formed Consensus Group on Outcome 
Measures Made in Paediatric Enteral Nutrition Clinical 
Trials (COMMENT) charged a working group to identify 
and define criteria for assessing key outcomes in paediat-
ric nutrition trials  [1] . In addition, this working group 
was asked to review and update the ‘core data set’ that 
should be recorded and reported in all clinical trials on 
infant nutrition, as first proposed in 2003 by the Euro-
pean Society for Paediatric Gastroenterology, Hepatolo-
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 Abstract 
 This paper presents an updated and revised summary of the 
‘core data set’ that has been proposed to be recorded and 
reported in all clinical trials on infant nutrition by the recent-
ly formed Consensus Group on Outcome Measures Made in 
Paediatric Enteral Nutrition Clinical Trials (COMMENT). This 
core data set was developed based on a previous proposal 
by the European Society for Paediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) Committee on Nutri-
tion in 2003. It comprises confidential data to identify sub-
jects and facilitate contact for further follow-up, data to char-
acterize the cohort studied and data on withdrawals from 
the study, and some additional core data for all nutrition 
studies on preterm infants. We recommend that all studies 
on nutrition in infancy should collect and report this core 
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gy and Nutrition (ESPGHAN) Committee on Nutrition 
 [2] . 
 The working group was constituted in 2011 and devel-
oped a draft version of the COMMENT by email ex-
change, which was discussed further and agreed up-
on during two physical meetings held in the first half of 
2012 and then submitted to a Delphi review process
by the chairs of all COMMENT working groups  [1] , the 
ESPGHAN Committees (www.espghan.org), the Theme 
Leaders of the European Commission-funded Early-
Nutrition Research Consortium (www.project-earlynu-
trition.eu) and the Nutrition Group of the European 
Society of Paediatric Research (www.espr.info). The 
working group reviewed the comments received and in-
corporated them into their final version.
General Concepts
 All clinical trials on nutritional interventions in in-
fants and children should follow current standards of 
good clinical practice, data monitoring, ethics and per-
sonal data protection  [3–5] . The reporting of the design 
and results of clinical trials should follow the updated 
‘Consolidated Standards of Reporting Trials’ (CON-
SORT) guidelines for reporting parallel-group ran-
domised trials  [6] and the extension of the CONSORT 
statement for reporting of harms in randomised trials 
 [7] . We suggest that the minimum core data set as de-
fined here should be recorded for all clinical trials on 
nutrition in infancy and childhood and be reported in all 
publications of such trials either as part of the main pa-
per or as supplementary material. Such consistent pre-
sentation of the characteristics of the populations stud-
ied will facilitate the interpretation and the comparison 
of findings of different studies as well as systematic re-
views and meta-analyses. In addition to these general 
core data, further data will need to be reported depend-
ing on the nature of the study and the chosen endpoints 
and approaches to outcome assessments that are ad-
dressed by other working groups of the COMMENT ini-
tiative.
 Identification Data 
 Data to identify subjects and facilitate contact for fur-
ther follow-up as suggested in  table 1 are not meant to be 
reported. In line with ethical principles and rules and reg-
ulations in place at the respective study sites, these confi-
dential data must be stored securely, and access must be 
restricted to a limited and predefined number of study 
personnel. However, these data are important to enable 
contact with parents or other caregivers during the study, 
and potentially after the planned study end for unfore-
seen extensions of the study or for addressing unforeseen 
safety issues. Increasingly, there are indications of long-
term effects of early interventions which are important to 
address. Researchers are encouraged to obtain consent 
for future contact with study participants upon enrol-
ment. 
 Data to Characterize the Cohort 
 Participants need to be well characterized, so that it is 
possible to determine whether participants are represen-
tative of the eligible population, and trial data can be more 
effectively compared (and, if relevant, aggregated) with 
data and results from other studies. The core data shown 
in  table 2 should be recorded and reported for all studies 
on infant nutrition. For studies on nutrition in preterm 
infants, additionally those listed in  table 3 should be re-
corded and reported.
 Data on Withdrawals from the Study 
 Details on subjects who withdraw, as well as the rea-
sons for withdrawal, must be recorded where possible 
and reported in order to address potential bias. Non-
compliance with the study protocol should not lead to 







Telephone numbers (home, mobile, work)
E-mail/social media
Name and address of the family doctor/paediatrician
Hospital identification number, social security number or
equivalent
Names, addresses and telephone numbers of relatives or close
friends
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withdrawal of subjects from the study; rather, non-com-
pliant subjects should be followed in the same way as sub-
jects who are concordant.
 Data indicating concordance or compliance should be 
collected in nutrition trials because they are important for 
the interpretation of trial results, even though primary 
statistical analyses will be performed on an intention-
to-treat basis. Concordance or compliance should be as-
sessed, for example, by obtaining prospective dietary re-
cords or structured interviews with caregivers, by collec-
tion of unused units of intervention products or weighing 
residual products in preweighed individual packages, by 
measurement of biomarkers in blood, urine or other sam-
ples, and by other suitable approaches. 
 Conclusions 
 It is recommended that all studies on nutrition in in-
fancy should collect and report the core data shown in 
 table 2 . Studies on nutrition in preterm infants should 
additionally collect the data in  tables 3–5 to facilitate in-
 Table 2.  Core data for all nutrition studies on infants
Gestation in completed weeks [report method of determination (based on ultrasound or the date of the last 
menstruation)]
Parity
Number of children in the household
Mode of delivery
Number of live-born infants from this pregnancy
Infant sex
Weight (g), length (cm) and head circumference (cm) at birth
Age at study recruitment 
Weight1 (g), length (cm) and head circumference (cm) at recruitment and at each assessment, along with the
age at study entry and at each assessment
Recording of infant feeding2
Whether fed human milk, formula or both (at study entry and at later time points)
Duration of exclusive human milk feeding (according to the definition of WHO, preferably in days)3
Duration of partial human milk feeding [i.e. feeding of human milk along with other energy-providing foods
such as formula, other energy-providing liquids or complementary feeds (energy-containing solid or
liquid foods fed to the infant other than breast milk or formula); duration to be reported preferably in days]
Duration of predominant human milk feeding (>80% of estimated energy intake)
Age (preferably in days) at the first introduction of formula feeding
Duration of exclusive formula feeding (preferably in days)
Type(s) of formula used and compositional characteristics
Supplements used, e.g. nutrient supplements or human milk fortifiers
Water (practiced in various parts of the world)
Age at the first introduction of complementary foods (preferably in days)
Father’s weight and height at the time of recruitment
Mother’s weight and height prior to/during the first 12 weeks of pregnancy or at the least 3 months after birth 
(time of measurement to be reported)
Maternal education (years of school and higher education)
Ethnicity/race of mother and father
Country of birth
Dominant language spoken at home
Maternal substance abuse (drugs/street drugs, smoking or alcohol), separately reported for pregnancy and for 
the postnatal period
 1 If standard deviation scores are reported, investigators should indicate whether they are based on the WHO 
growth standard or on other growth references.
2 It should be reported whether data were collected pro- or retrospectively, and how they were obtained (e.g. 
3-day dietary record filled out by parents, 24-hour recall interview, data collection from hospital files or other). 
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terpretation and comparison of results from clinical 
studies and of systematic data evaluation and meta-anal-
yses. Obviously, further data in addition to this core data 
set will need to be reported depending on the specific 
design and goals of the studies. Editors of journals pub-
lishing such reports are encouraged to require the report-
ing of the minimum data set described here either in the 
main body of the publication or as supplementary online 
material. 
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 Table 3.  Additional core data for all nutrition studies on preterm infants
Antenatal steroid treatment
Postnatal steroid treatment
Days with assisted ventilation (including mechanical ventilation and continuous positive airway pressure)1
Days with supplementary oxygen1
Number of infective episodes treated with antibiotics and of culture-positive events
Number of nosocomial infections2
Necrotising enterocolitis (criteria for grading as in table 4)
Surgery (yes or no, and reason)
Intraventricular haemorrhage (criteria for grading as in table 5)
Death before discharge home (yes or no, age in days if yes)
Age at discharge to home (days)
Recording of infant feeding:
Days on intravenous feeding (with information on the type of amino acid and lipid emulsion)1
Age (days) when enteral feeding first commenced
Age (days) when first having >120 ml/kg as enteral feeding
Proportion of intake (% volume of total enteral feeding) as mother’s own milk
Proportion of intake as donor human milk (% volume of total enteral feeding)
 1 ≥4 h in any 24-hour period counts as a day.
2 Nosocomial infection was defined as (1) a positive bacterial culture of blood or cerebrospinal fluid obtained 
≥72 h after birth or (2) a positive blood or cerebrospinal fluid culture for coagulase-negative Staphylococcus ob-
tained 72 h or more after birth and associated with generalised symptoms of illness for which the infant received 
antibiotics for ≥5 days [8].
 Table 4.  Necrotising enterocolitis (coding based on the severity of 
the illness according to the staging criteria of Bell et al. [9] and 
modifications of Kliegman and Walsh [10])
Stage I (suspect) clinical signs and symptoms,
non-diagnostic radiographs
Stage II (definite) clinical signs and symptoms,
pneumatosis intestinalis on radiograph
IIa mildly ill
IIb moderately ill with systemic toxicity
Stage III (advanced) clinical signs and symptoms, 
pneumatosis intestinalis on radiograph and 
critically ill
IIIa impending intestinal perforation
IIIb proven intestinal perforation
 Table 5.  Cerebral lesions: germinal matrix/intraventricular haem-
orrhage (from Volpe and de Vries [11])
Grade 1 germinal matrix haemorrhage
Grade 2 intraventricular blood without distension of the 
ventricular system
Grade 3 blood filling and distension of the ventricular system
Grade 4 parenchymal involvement of haemorrhage, also 
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